title: Prospective comparison of topical moxifloxacin in eliminating conjunctival bacterial flora following a one-day or one-hour application.
abstract: OBJECTIVE
  The aim of this study was to compare the efficacy of a 1-hour(h) versus 1-day application of topical moxifloxacin in eliminating conjunctival bacterial flora.
  
  
  METHODS
  In this prospective, nonrandomized, controlled trial, the surgical eyes of 60 patients scheduled for intraocular surgery received topical moxifloxacin four times a day, starting 1 day prior to surgery and three additional applications at 5-minute intervals 1 h before surgery. The nonsurgical eye of each patient only received three applications of the same antibiotic at 5-minute intervals 1 h before surgery. Conjunctival cultures were obtained at baseline and after antibiotic application.
  
  
  RESULTS
  Prior to antibiotic application, 80% of surgical eyes and 70% of nonsurgical eyes had positive cultures. Following the 1-day application, significantly fewer eyes (40%) had positive cultures (P < 0.0001), with a further reduction to 32% with three additional doses 1 h prior to surgery. In the nonsurgical eye, the decrease in the percentage of positive cultures, from 55% to 53% following the three applications 1 h prior to surgery, was not significant (P > 0.9999). The 1-day application was associated with significantly fewer positive cultures, compared to the 1-h group (P = 0.0267).
  
  
  CONCLUSIONS
  The one-day application of moxifloxacin resulted in significantly fewer positive conjunctival cultures, compared with a 1-h application.
authors.affiliation: Department of Ophthalmology, School of Medicine, Stanford University, Stanford, CA 94304, USA. cta@stanford.edu
authors.forename: Christopher N
authors.initials: CN
authors.lastname: Ta
authors.forename: Ian
authors.initials: I
authors.lastname: Chan
authors.forename: Harpreet Singh
authors.initials: HS
authors.lastname: Dhatt
authors.forename: Josemaria
authors.initials: J
authors.lastname: Paterno
authors.forename: Emily
authors.initials: E
authors.lastname: Fisher
authors.forename: Kuldev
authors.initials: K
authors.lastname: Singh
authors.forename: Artis
authors.initials: A
authors.lastname: Montague
authors.forename: Peter R
authors.initials: PR
authors.lastname: Egbert
authors.forename: Glenn
authors.initials: G
authors.lastname: Cockerham
authors.forename: Herminia Mino De
authors.initials: HM
authors.lastname: Kaspar
mesh_terms: D000287:Administration, Topical; D000368:Aged; D001372:Aza Compounds / Q000008:administration & dosage*; D003234:Conjunctivitis, Bacterial / Q000188:drug therapy* / Q000382:microbiology*; D004334:Drug Administration Schedule; D015818:Eye Infections, Bacterial / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D000077266:Moxifloxacin; D011446:Prospective Studies; D011804:Quinolines / Q000008:administration & dosage*; D013997:Time Factors
chemical_list: D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin